Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (58)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Chen, X.
Right arrow Articles by Yang, C. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, X.
Right arrow Articles by Yang, C. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis, Vol. 22, No. 8, 1119-1129, August 2001
© 2001 Oxford University Press

REVIEW

Esophageal adenocarcinoma: a review and perspectives on the mechanism of carcinogenesis and chemoprevention

Xiaoxin Chen and Chung S. Yang1,

Laboratory for Cancer Research, College of Pharmacy, Rutgers, The State University of New Jersey, 164 Frelinghuysen Road, Piscataway, NJ 08854, USA

The incidence rate of esophageal adenocarcinoma (EAC) has increased sharply in the past 30 years. Many risk factors have been identified and gastroesophageal reflux disease (GERD) is the most important one. Columnar-lined esophagus, resulting from GERD, is recognized as a key precursor lesion of EAC. In this article, we review the studies on EAC in humans and animal models. We propose that the pathogenesis of EAC is mainly driven by inflammation and oxidative stress, which are augmented by iron overload. The overproduction of prostaglandin E2 and leukotriene B4 and overexpression of their receptors are believed to be major factors in exacerbating inflammation and oxidative stress. Based on this mechanistic understanding, antioxidants, inhibitors of arachidonic acid metabolism enzymes and receptor antagonists of certain eicosanoids are proposed as potential chemopreventive agents for EAC in future studies.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Prevention ResearchHome page
M. J. Blaser
Disappearing Microbiota: Helicobacter pylori Protection against Esophageal Adenocarcinoma
Cancer Prevention Research, October 1, 2008; 1(5): 308 - 311.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Boult, K. Roberts, M. J. Brookes, S. Hughes, J. P. Bury, S. S. Cross, G. J. Anderson, R. Spychal, T. Iqbal, and C. Tselepis
Overexpression of Cellular Iron Import Proteins Is Associated with Malignant Progression of Esophageal Adenocarcinoma
Clin. Cancer Res., January 15, 2008; 14(2): 379 - 387.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. C.G. Martin, Q. Liu, J. M. Wo, M. B. Ray, and Y. Li
Chemoprevention of Carcinogenic Progression to Esophageal Adenocarcinoma by the Manganese Superoxide Dismutase Supplementation
Clin. Cancer Res., September 1, 2007; 13(17): 5176 - 5182.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
Y. Li, J. M. Wo, R. R. Su, M. B. Ray, and R. C. G. Martin
Alterations in Manganese Superoxide Dismutase Expression in the Progression From Reflux Esophagitis to Esophageal Adenocarcinoma
Ann. Surg. Oncol., July 1, 2007; 14(7): 2045 - 2055.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
T. Liu, X. Zhang, C.-K. So, S. Wang, P. Wang, L. Yan, R. Myers, Z. Chen, A. P. Patterson, C. S. Yang, et al.
Regulation of Cdx2 expression by promoter methylation, and effects of Cdx2 transfection on morphology and gene expression of human esophageal epithelial cells
Carcinogenesis, February 1, 2007; 28(2): 488 - 496.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Arguello, S. Paz, E. Hernandez, C. Corriveau-Bourque, L. M. Fawaz, J. Hiscott, and R. Lin
Leukotriene A4 Hydrolase Expression in PEL Cells Is Regulated at the Transcriptional Level and Leads to Increased Leukotriene B4 Production.
J. Immunol., June 1, 2006; 176(11): 7051 - 7061.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
S. R. DeMeester
Adenocarcinoma of the Esophagus and Cardia: A Review of the Disease and Its Treatment
Ann. Surg. Oncol., January 1, 2006; 13(1): 12 - 30.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. R. Olliver, L. J. Hardie, Y. Gong, S. Dexter, D. Chalmers, K. M. Harris, and C. P. Wild
Risk Factors, DNA Damage, and Disease Progression in Barrett's Esophagus
Cancer Epidemiol. Biomarkers Prev., March 1, 2005; 14(3): 620 - 625.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
K. Oyama, T. Fujimura, I. Ninomiya, T. Miyashita, S. Kinami, S. Fushida, T. Ohta, and M. Koichi
A COX-2 inhibitor prevents the esophageal inflammation-metaplasia-adenocarcinoma sequence in rats
Carcinogenesis, March 1, 2005; 26(3): 565 - 570.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
P. S. Dahlberg, B. A. Jacobson, G. Dahal, J. M. Fink, R. A. Kratzke, M. A. Maddaus, and L. J. Ferrin
ERBB2 Amplifications in Esophageal Adenocarcinoma
Ann. Thorac. Surg., November 1, 2004; 78(5): 1790 - 1800.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
X. Chen, S. Wang, N. Wu, S. Sood, P. Wang, Z. Jin, D. G. Beer, T. J. Giordano, Y. Lin, W.-c. J. Shih, et al.
Overexpression of 5-Lipoxygenase in Rat and Human Esophageal Adenocarcinoma and Inhibitory Effects of Zileuton and Celecoxib on Carcinogenesis
Clin. Cancer Res., October 1, 2004; 10(19): 6703 - 6709.
[Abstract] [Full Text] [PDF]

Home page
 MutagenesisHome page
A.J. Jolly, C.P. Wild, and L.J. Hardie
Acid and bile salts induce DNA damage in human oesophageal cell lines
Mutagenesis, July 1, 2004; 19(4): 319 - 324.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
H. Kumagai, K.-i. Mukaisho, H. Sugihara, K. Miwa, G. Yamamoto, and T. Hattori
Thioproline inhibits development of esophageal adenocarcinoma induced by gastroduodenal reflux in rats
Carcinogenesis, May 1, 2004; 25(5): 723 - 727.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
P. S. Dahlberg, L. F. Ferrin, S. M. Grindle, C. M. Nelson, C. D. Hoang, and B. Jacobson
Gene expression profiles in esophageal adenocarcinoma
Ann. Thorac. Surg., March 1, 2004; 77(3): 1008 - 1015.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
E. I. T. Sihvo, T. Ruohtula, M. I. Auvinen, A. Koivistoinen, A. L. Harjula, and J. A. Salo
Simultaneous progression of oxidative stress and angiogenesis in malignant transformation of Barrett esophagus
J. Thorac. Cardiovasc. Surg., January 1, 2004; 126(6): 1952 - 1957.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
X. Chen, N. Li, S. Wang, N. Wu, J. Hong, X. Jiao, M. J. Krasna, D. G. Beer, and C. S. Yang
Leukotriene A4 Hydrolase in Rat and Human Esophageal Adenocarcinomas and Inhibitory Effects of Bestatin
J Natl Cancer Inst, July 16, 2003; 95(14): 1053 - 1061.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
A. G. Casson, S. C. Evans, A. Gillis, G. A. Porter, P. Veugelers, S. J. Darnton, D. L. Guernsey, and P. Hainaut
Clinical implications of p53 tumor suppressor gene mutation and protein expression in esophageal adenocarcinomas: Results of a ten-year prospective study
J. Thorac. Cardiovasc. Surg., May 1, 2003; 125(5): 1121 - 1131.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
X. Chen, N. Li, S. Wang, J. Hong, M. Fang, J. Yousselfson, P. Yang, R. A. Newman, R. A. Lubet, and C. S. Yang
Aberrant arachidonic acid metabolism in esophageal adenocarcinogenesis, and the effects of sulindac, nordihydroguaiaretic acid, and {alpha}-difluoromethylornithine on tumorigenesis in a rat surgical model
Carcinogenesis, December 1, 2002; 23(12): 2095 - 2102.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Greenwald
Cancer Prevention Clinical Trials
J. Clin. Oncol., September 15, 2002; 20(90001): 14s - 22.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.